Meningococcal Disease Clinical Trial
Official title:
An Observational Follow up Study of a Phase II/III, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Meningococcal ACWY Conjugate Vaccine (Menveo, Glaxosmithkline or Nimenrix, Pfizer) in Adolescents Who Were Primed With Meningitec, Menjugate or Neisvac-C During Preschool Vaccination
A previous cohort of 93 clinical trial participants received quadrivalent meningococcal
conjugate vaccine, which includes strains ACW and Y, in their teenage years. The vaccine also
contains components of diphtheria and tetanus which are linked to the meningitis components,
in a process called conjugation, to improve their effectiveness.
Participants are now aged 19-25 and will be invited to take part in this study, which will
assess antibody persistence over time. This will provide information about the duration of
protection by relating current antibody levels to those measured in the previous study, and
will underpin the national immunisation schedule in providing optimal immunisation schedule.
As well as the meningitis antibodies the investigators will assess diphtheria and tetanus
antibody levels.
The study will involve a single blood test of up to 8mL. Participants will be informed of
their results and any with an antibody level that does not infer protection against strain W
will be offered an extra dose of vaccine as part of a duty of care.
The study will involve a single blood test of up to 8mL. Participants will be informed of
their results and any with an antibody level that does not infer protection against strain W
will be offered an extra dose of vaccine.
The UK was the first country in the world to introduce the meningococcal serogroup C
conjugate vaccine (MCC) into its routine immunisation schedule in 1999. This very effectively
reduced the incidence of disease, which was highest in those younger than 1 year through its
routine use in the infant immunisation schedule, and those aged around 15-17 years through a
catch up campaign . Subsequently, the meningococcal vaccination schedule has undergone
several revisions, including:
- 2006 - a reduction in the number of doses given to infants from the manufacturer advised
three to the JCVI instructed two with the combination of the MCC dose in the second year
of life with the Hib vaccine, in the form of Menitorix
- 2013 - a further reduction to a single dose in infancy and the introduction of a booster
in teenage years due to studies demonstrating that antibody persistence was short lived
through childhood
- 2015 - the amendment of the teenage booster dose from MCC to a quadrivalent
meningococcal conjugate vaccine to address the increasing incidence of serogroup W
disease in this age group (PHE website - Meningococcal data), and the introduction of
Bexsero into the infant schedule ostensibly to address meningococcal B disease but with
the potential for cross protection against other serogroups, which is currently being
assessed in another NVEC study.
- 2016 - removal of the MCC at 3 months of age.
Given the previous demonstration of poor antibody persistence of MenC antibodies two years
following the 2006 schedule, with only 43%, 22% and 23% of children achieving SBA titres ≥8
two years following a booster dose of Menitorix™ when primed with NeisVac-C™, Menjugate™ and
Meningitec™, respectively, there is concern about the protection afforded by the quadrivalent
vaccine administered at around 14 years of age, and whether this will provide protection into
young adulthood when the risk of disease is high.
In a previous study by this group (Eudract number 2010-022505-18) , adolescents aged 16-19
years were randomised to receive one of two licensed meningococcal ACWY conjugate vaccines:
1. Menveo™ (GSK) This vaccine contains bacterial capsular oligosaccharides for serogroups
A, C, W, and Y conjugated to a protein carrier, CRM197, which is a nontoxigenic natural
variant of diphtheria toxin. The MenACWY vaccine has been tested in several age groups
and has been shown to be generally well tolerated and immunogenic. Menveo™ is indicated
for use in those from 2 years of age and in those at risk.
2. Nimenrix (Pfizer) This vaccine contains bacterial capsular oligosaccharides for
serogroups A, C, W, and Y conjugated to Tetanus Toxoid (TT). This MenACWY-TT vaccine has
been tested in several age groups and has been shown to be safe and immunogenic. It is
indicated for use from 12 months of age and in those at risk.
The cohort included in this study was one of the first to receive meningococcal C conjugate
vaccine as young children, and subsequently to have the booster in the form of meningococcal
quadrivalent (ACWY) conjugate vaccination at age 16-19 years. This group of 93 young adults,
now aged 20-24 years, provides a unique opportunity to study the persistence of meningococcal
serogroup-specific antibodies over time. This is particularly important given the recent
increases in incidence of meningococcal W disease which prompted the amendment of the
national schedule to include a booster of the meningococcal quadrivalent vaccine in teenage
years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Completed |
NCT01434680 -
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
|
Phase 2 | |
Completed |
NCT01452438 -
Safety Surveillance of MenACWY-CRM Vaccine in Children
|
N/A | |
Completed |
NCT01452464 -
Safety of MenACWY-CRM Vaccination in Adolescents
|
N/A | |
Completed |
NCT02173704 -
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
|
Phase 3 | |
Completed |
NCT01682876 -
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
|
Phase 3 | |
Recruiting |
NCT04023929 -
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
|
||
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT01214837 -
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
|
Phase 3 | |
Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
Recruiting |
NCT04239430 -
Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
|
||
Completed |
NCT01994629 -
Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
|
Phase 2 | |
Completed |
NCT01973218 -
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
|
Phase 3 | |
Completed |
NCT01717638 -
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
|
Phase 3 | |
Completed |
NCT01725217 -
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
|
Phase 3 | |
Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
Completed |
NCT01000311 -
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
|
Phase 3 | |
Completed |
NCT02141516 -
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
|
Phase 3 | |
Completed |
NCT02140762 -
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
|
Phase 2 | |
Completed |
NCT01478347 -
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
|
Phase 3 |